Zoetis Inc (NYSE:ZTS) Insider Sells $756,251.73 in Stock
Zoetis Inc (NYSE:ZTS) insider Clinton A. Jr. Lewis sold 6,123 shares of Zoetis stock in a transaction on Wednesday, August 14th. The stock was sold at an average price of $123.51, for a total transaction of $756,251.73. Following the transaction, the insider now directly owns 44,255 shares of the company’s stock, valued at $5,465,935.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
NYSE ZTS traded up $1.89 during trading on Thursday, hitting $123.68. 1,604,963 shares of the company’s stock were exchanged, compared to its average volume of 2,151,553. The company has a debt-to-equity ratio of 2.74, a quick ratio of 2.87 and a current ratio of 4.17. The stock has a market capitalization of $59.19 billion, a P/E ratio of 39.51, a PEG ratio of 3.13 and a beta of 0.92. Zoetis Inc has a fifty-two week low of $78.90 and a fifty-two week high of $125.88. The firm’s 50 day moving average price is $116.11.
Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, August 6th. The company reported $0.90 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.82 by $0.08. The firm had revenue of $1.55 billion during the quarter, compared to the consensus estimate of $1.51 billion. Zoetis had a return on equity of 72.86% and a net margin of 22.74%. The business’s quarterly revenue was up 9.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.77 earnings per share. On average, equities analysts predict that Zoetis Inc will post 3.57 earnings per share for the current year.
A number of research firms have commented on ZTS. Barclays lifted their price objective on shares of Zoetis from $120.00 to $135.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. Bank of America cut shares of Zoetis from a “buy” rating to a “neutral” rating and lifted their price objective for the stock from $111.00 to $120.00 in a research report on Monday, July 1st. They noted that the move was a valuation call. Stifel Nicolaus lifted their price objective on shares of Zoetis from $110.00 to $130.00 and gave the stock a “buy” rating in a research report on Monday, July 22nd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $130.00 price objective (up from $116.00) on shares of Zoetis in a research report on Wednesday, June 12th. Finally, Guggenheim assumed coverage on shares of Zoetis in a research report on Thursday, May 23rd. They set a “buy” rating and a $114.00 price objective for the company. Seven research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $115.13.
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Further Reading: Trading Ex-Dividend Strategy
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.